313 related articles for article (PubMed ID: 29135906)
1. Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.
Cvetković M; Zivković M; Bundalo M; Gojković I; Spasojević-Dimitrijeva B; Stanković A; Kostić M
Ther Drug Monit; 2017 Dec; 39(6):589-595. PubMed ID: 29135906
[TBL] [Abstract][Full Text] [Related]
2. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
Elens L; Hesselink DA; Bouamar R; Budde K; de Fijter JW; De Meyer M; Mourad M; Kuypers DR; Haufroid V; van Gelder T; van Schaik RH
Ther Drug Monit; 2014 Feb; 36(1):71-9. PubMed ID: 24061445
[TBL] [Abstract][Full Text] [Related]
3. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
Lunde I; Bremer S; Midtvedt K; Mohebi B; Dahl M; Bergan S; Åsberg A; Christensen H
Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827
[TBL] [Abstract][Full Text] [Related]
4. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
[TBL] [Abstract][Full Text] [Related]
6. Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis.
Wang CE; Lu KP; Chang Z; Guo ML; Qiao HL
Gene; 2018 Jul; 664():44-49. PubMed ID: 29678659
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
8. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study.
Gijsen VM; van Schaik RH; Soldin OP; Soldin SJ; Nulman I; Koren G; de Wildt SN
Ther Drug Monit; 2014 Apr; 36(2):152-8. PubMed ID: 24089076
[TBL] [Abstract][Full Text] [Related]
9. A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients.
Jannot AS; Vuillemin X; Etienne I; Buchler M; Hurault de Ligny B; Choukroun G; Colosio C; Thierry A; Vigneau C; Moulin B; Rerolle JP; Heng AE; Subra JF; Legendre C; Beaune P; Loriot MA; Thervet E; Pallet N
Ther Drug Monit; 2016 Apr; 38(2):223-9. PubMed ID: 26829596
[TBL] [Abstract][Full Text] [Related]
10. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
[TBL] [Abstract][Full Text] [Related]
12. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
Li DY; Teng RC; Zhu HJ; Fang Y
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867
[TBL] [Abstract][Full Text] [Related]
13. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
[TBL] [Abstract][Full Text] [Related]
15. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.
Qiu XY; Jiao Z; Zhang M; Zhong LJ; Liang HQ; Ma CL; Zhang L; Zhong MK
Eur J Clin Pharmacol; 2008 Nov; 64(11):1069-84. PubMed ID: 18636247
[TBL] [Abstract][Full Text] [Related]
16. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.
de Jonge H; Metalidis C; Naesens M; Lambrechts D; Kuypers DR
Pharmacogenomics; 2011 Sep; 12(9):1281-91. PubMed ID: 21770725
[TBL] [Abstract][Full Text] [Related]
17. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
[TBL] [Abstract][Full Text] [Related]
18. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
[TBL] [Abstract][Full Text] [Related]
19. CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.
Lesche D; Sigurdardottir V; Setoud R; Oberhänsli M; Carrel T; Fiedler GM; Largiadèr CR; Mohacsi P; Sistonen J
Ther Drug Monit; 2014 Dec; 36(6):710-5. PubMed ID: 24739669
[TBL] [Abstract][Full Text] [Related]
20. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]